Related Experiment Video
Updated: Mar 25, 2026
08:46
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
11.3K
Educational innovations in clinical pharmacogenomics
C G Perry1,2, K A Maloney2,3, A L Beitelshees2,3
1Program in Epidemiology and Human Genetics, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Clinical Pharmacology and Therapeutics
|February 15, 2016
Summary
Genomic medicine advances understanding of diseases and treatments. Medical schools must update curricula to train physicians in genetic testing and genomic medicine integration for improved patient care.
Area of Science:
- Genomic Medicine
- Medical Education
Background:
- Genetic and genomic discoveries are rapidly advancing medical understanding and patient treatments.
- This progress necessitates updating medical education to incorporate new genomic technologies and clinical applications.
Purpose of the Study:
- To highlight the urgent need for medical school curriculum expansion in genetic and genomic testing.
- To emphasize the importance of integrating genomic medicine into clinical practice and physician training.
Main Methods:
- Review of current trends in genetic and genomic discovery.
- Analysis of recommendations from healthcare organizations and authorities regarding medical education.
Main Results:
- The rapid pace of genomic discovery requires immediate curriculum reform in medical schools.
- Physicians need to be trained in genetic and genomic testing, including pharmacogenomics, and the clinical application of genomic medicine.
Conclusions:
- Medical schools are tasked with equipping future physicians with essential genomic knowledge and clinical skills.
- Competency in genomic implementation is crucial for advancing patient care through personalized medicine.
More Related Videos
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
76
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
76
01:29Pharmacogenetics and Pharmacogenomics: Overview
138
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
138
01:27Pharmacogenetics of Drug Metabolism: Overview
107
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
107
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
108
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
108
01:27Principles of Pharmacogenetics: Types of Genetic Variants
88
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
88
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
125
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
125